TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25416753
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of wild-type A(H1N1)pdm09 virus at an optimal dose of 10(7) tissue culture infectious dose 50.
Study: 25416753
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of wild-type A(H1N1)pdm09 virus.
Study: 25416807
Drug: Daclizumab therapy
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclizumab therapy
Study: 25417733
Drug: 50 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 Gy total dose with target volumes defined on pre-RT FDG-PET/CT
Study: 25417902
Drug: Trametinib 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trametinib 1.5 mg/afuresertib 50 mg once daily continuously
Study: 25417902
Drug: Trametinib 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trametinib 1.5 mg/afuresertib 25 mg
Study: 25417902
Drug: Trametinib 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trametinib 1.0 mg/afuresertib 50 mg
Study: 25417902
Drug: Trametinib 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trametinib 1.5 mg (continuous)/afuresertib 50 mg (Days 1-10 every 28 days)
Study: 25417902
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of trametinib and afuresertib
Study: 25417909
Drug: Antiviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral treatment (AT)
Study: 25420620
Drug: IVF/ICSI (In
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVF/ICSI (In Vitro Fertilization/Intracytoplasmic Sperm Injection)
Study: 25422771
Drug: Glimepiride/metformin fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride/metformin fixed-dose combination (G/M FDC)
Study: 25422771
Drug: Metformin uptitration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin uptitration (Met UP)
Study: 25423570
Drug: TESE for
Normalized name: Tesetaxel
DrugBank: Tesetaxel (DB12019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TESE for patients with previous testosterone treatment
Study: 25423570
Drug: TESE for
Normalized name: Tesetaxel
DrugBank: Tesetaxel (DB12019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TESE for patients without previous testosterone treatment
Study: 25425121
Drug: Agalsidase alfa
Normalized name: Agalsidase alfa
DrugBank: Agalsidase alfa (DB15874)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Agalsidase alfa (0.2 mg/kg, intravenous, every-other-week)
Study: 25426701
Drug: Biphasic human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic human insulin 30 (BHI)
Study: 25426834
Drug: cAd3-EBO vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cAd3-EBO vaccine (2×10^11 viral particles)
Study: 25428714
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ZPP with haemoglobin concentration
Study: 25428822
Drug: Primary endovascular
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary endovascular therapy
Study: 25428822
Drug: Primary endovascular
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary endovascular therapy (within 180-270 min)
Study: 25428822
Drug: Primary endovascular
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary endovascular therapy (severe strokes)
Study: 25429521
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin K antagonists
Study: 25429526
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m² plus cisplatin 70 mg/m² on day 1 every 3 weeks
Study: 25430947
Drug: Intramuscular IFN-β-1a
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular IFN-β-1a autoinjector
Study: 25432532
Drug: Emergency video
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency video capsule endoscopy (VCE)
Study: 25435055
Drug: HPV types
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV types in the quadrivalent vaccine (anal)
Study: 25435055
Drug: HPV types
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV types in the quadrivalent vaccine (penile)
Study: 25435886
Drug: placebo/no treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo/no treatment
Study: 25438151
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus GG ATCC 53103 (LGG) 1×10^10 CFU, orally, twice daily for 28 days
Study: 25439363
Drug: Budesonide-formoterol combination
Normalized name: budesonide / formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide-formoterol combination (BFC)
Study: 25439363
Drug: Fluticasone-salmeterol combination
Normalized name: FLUTICASONE/SALMETEROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone-salmeterol combination (FSC)
Study: 25441108
Drug: Ruxolitinib 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib 50 mg b.i.d. (n = 4)
Study: 25441108
Drug: Ruxolitinib 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib 100 mg b.i.d. (n = 5)
Study: 25441108
Drug: Ruxolitinib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib 200 mg b.i.d. (n = 18)
Study: 25442036
Drug: Contura multilumen
Normalized name: Pinus contorta pollen
DrugBank: Pinus contorta pollen (DB10894)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contura multilumen balloon (CMLB) breast brachytherapy catheter delivering accelerated partial breast irradiation (APBI) with a total dose of 34 Gy in 10 fractions, delivered twice daily.
Study: 25442039
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) with a dose of 42 Gy/3 fractions for targets ≥5 cm and 26 Gy/1 fraction for targets <5 cm.
Study: 25442806
Drug: Intravenous metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous metronidazole (MNZ) combined with ceftriaxone (CTRX) at doses of 500 mg 3 or 4 times a day/1 or 2 g twice a day
Study: 25442806
Drug: Intravenous metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous metronidazole (MNZ) combined with ceftriaxone (CTRX)
Study: 25446240
Drug: Implant-retained FDPs
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implant-retained FDPs
Study: 25446831
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of A/Netherlands/219/03 (H7N7) pLAIV (10^7.5 TCID50 intranasally)
Study: 25446831
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of A/chicken/British Columbia/CN-6/04 (H7N3) pLAIV (10^7.5 TCID50 intranasally)
Study: 25446831
Drug: One 45
Normalized name: idebenone 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 45 μg dose of H7N7 pIIV (intramuscularly)
Study: 25448923
Drug: Mucosal impedance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucosal impedance (MI) measurement before and after acid suppressive therapy
Study: 25450031
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg daily and docetaxel 60 mg/m(2)
Study: 25450151
Drug: Sentinel lymph
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sentinel lymph node (SLN) biopsy after cervical dual injection (technetium and patent blue) and systematic pelvic node dissection
Study: 25451051
Drug: Intravenous voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous voriconazole 9 mg/kg followed by 8 mg/kg every 12 hours, and oral voriconazole 9 mg/kg (max 350 mg) every 12 hours for patients <50 kg or 6 mg/kg followed by 4 mg/kg every 12 hours and 200 mg oral voriconazole every 12 hours for patients ≥50 kg
Study: 25451053
Drug: ABT-450 at
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-450 at highest dose
Study: 25451055
Drug: Ombitasvir 5
Normalized name: Ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ombitasvir 5 mg
Study: 25451055
Drug: Ombitasvir 25
Normalized name: Ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ombitasvir 25 mg
Study: 25451055
Drug: Ombitasvir 50
Normalized name: Ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ombitasvir 50 mg
Study: 25451055
Drug: Ombitasvir 200
Normalized name: Ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ombitasvir 200 mg
Study: 25451055
Drug: Ombitasvir (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ombitasvir (all doses)
Study: 25451055
Drug: Ombitasvir (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ombitasvir (doses higher than 5 mg)
Study: 25452591
Drug: A. vaginae
Approvals — FDA: no, EMA: no, PMDA: no
Description: A. vaginae levels ≥10(8) copies/mL
Study: 25452708
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist 0.25 mg
Study: 25454012
Drug: Asthma identification
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Asthma identification and medication administration forms
Study: 25456362
Drug: Dacomitinib (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacomitinib (45 mg or 30 mg orally once daily) until progressive disease, unacceptable toxicity, or patient withdrawal
Study: 25456362
Drug: Dacomitinib (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacomitinib (45 mg or 30 mg orally once daily)
Study: 25456368
Drug: Docetaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (100 mg/m(2) intravenously every 3 weeks) plus trastuzumab (8 mg/kg intravenously every 3 weeks then 6 mg/kg intravenously every 3 weeks for the second course)
Study: 25456368
Drug: Docetaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (100 mg/m(2) intravenously every 3 weeks) plus trastuzumab (6 mg/kg intravenously every 3 weeks) plus bevacizumab (15 mg/kg intravenously every 3 weeks; group A)
Study: 25456368
Drug: Docetaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (100 mg/m(2) intravenously every 3 weeks) plus trastuzumab (6 mg/kg intravenously every 3 weeks; group B)
Study: 25456369
Drug: Oral ixazomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ixazomib (2.97 mg/m2) plus lenalidomide 25 mg and dexamethasone 40 mg for up to 12 cycles, followed by maintenance therapy with ixazomib alone.
Study: 25456369
Drug: Oral ixazomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ixazomib (3.95 mg/m2) in phase 1.
Study: 25456369
Drug: Oral ixazomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ixazomib (2.23 mg/m2, converted to 4.0 mg fixed dose) in phase 2.
Study: 25457458
Drug: Baseline glomerular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline glomerular filtration rate <30 mL/min/1.73 m(2)
Study: 25457633
Drug: Dovitinib 500
Normalized name: Dovitinib
DrugBank: Dovitinib (DB05928)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dovitinib 500 mg once daily on a 5-days-on/2-days-off schedule
Study: 25459109
Drug: Control mice
Normalized name: Douxo Micellar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control mice injected with unlabeled BzDTPA-pertuzumab (20μg) or Sodium Chloride Injection USP
Study: 25460357
Drug: Unrelated cord
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unrelated cord blood transplantation (UCBT) using reduced-intensity conditioning (RIC) consisting of total body irradiation (2 Gy), cyclophosphamide (50 mg/kg), and fludarabine (200 mg/m(2)).
Study: 26133811
Drug: Lacosamide (100-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide (100-800 mg/day)
Study: 25462205
Drug: Vinorelbine 25mg/m(2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 25mg/m(2) followed by gemcitabine 1000mg/m(2) administered intravenously on days 1 and 8 every 3 weeks
Study: 25462205
Drug: Vinorelbine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine and gemcitabine combination chemotherapy
Study: 25464836
Drug: Behavioral Activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Activation therapy (BA-W) for 12 weeks
Study: 25465231
Drug: High-dose treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose treatment arm
Study: 25465273
Drug: Insulin-treated patients
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-treated patients with T1DM
Study: 25465273
Drug: Insulin-treated patients
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-treated patients with T2DM
Study: 25468505
Drug: Concurrent validity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent validity assessments
Study: 25468512
Drug: Lacosamide 300
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lacosamide 300 mg/day
Study: 25470338
Drug: Tofacitinib 10
Normalized name: tofacitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 10 mg twice daily for 6 weeks
Study: 25470818
Drug: Intravenous zanamivir
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zanamivir (IVZ) 600 mg twice daily for five days
Study: 25473029
Drug: Anidulafungin 200
Normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anidulafungin 200 mg every 48 h
Study: 25473029
Drug: Anidulafungin 300
Normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anidulafungin 300 mg every 72 h
Study: 25473804
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of NT-proBNP and NGAL
Study: 25473804
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of BNP and NGAL
Study: 25474185
Drug: Gene expression
Normalized name: Antisense Oligonucleotide Inhibitor Of The Expression Of Superoxide Dismutase 1 Gene
DrugBank: Tofersen (DB14782)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene expression of toll-like receptor 4, catalase, and tumor necrosis factor-α
Study: 25474185
Drug: Biomarkers in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomarkers in exhaled breath condensate and airway resistance (pre- and post-bronchodilator)
Study: 25475601
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg once daily for 5 days followed by warfarin loading dose of 5 or 10 mg once daily for 2-4 days (co-administration)
Study: 25475601
Drug: Warfarin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin alone (monotherapy)
Study: 25476715
Drug: Serum bilirubin
Normalized name: bilirubin preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum bilirubin levels >1.1 mg/dL in patients with no appendiceal inflammation (14%) vs any appendicitis (36%)
Study: 25476715
Drug: Serum bilirubin
Normalized name: bilirubin preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum bilirubin levels >1.1 mg/dL in patients with non-perforated appendicitis (48%) vs perforated appendicitis
Study: 25478017
Drug: AADvac1 tau
Normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AADvac1 tau peptide vaccine
Study: 25478142
Drug: Active chiropractic
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active chiropractic treatment
Study: 25478142
Drug: Sham chiropractic
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham chiropractic treatment
Study: 25478681
Drug: Initial tidal
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial tidal volume of 1 ml/kg PBW increase
Study: 25478681
Drug: Subsequent tidal
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent tidal volume of 1 ml/kg PBW increase
Study: 25478681
Drug: Receiving 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receiving 10 ml/kg PBW for 8 days
Study: 25478681
Drug: Receiving 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receiving 8 ml/kg PBW for 8 days
Study: 25480497
Drug: Age-adjusted multi-agent
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age-adjusted multi-agent immunochemotherapy regimen with temozolomide maintenance
Study: 25481376
Drug: Depot medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot medroxyprogesterone acetate (DMPA) administered within 15 min of mifepristone administration
Study: 25481820
Drug: Glucagon stimulation
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon stimulation test (GST) with 1mg of glucagon via intramuscular injection
Study: 25482244
Drug: Orthostat-L™ (hemostatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthostat-L™ (hemostatic putty loaded with lidocaine)
Study: 25483909
Drug: Treatment discontinuation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment discontinuation reasons
Study: 25486412
Drug: Chemotherapy (5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (5-fluorouracil with interferon-α and gemcitabine with oxaliplatin)
Study: 25486575
Drug: Stem cell-based
Normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stem cell-based therapies
Study: 25488930
Drug: 140 mg
Normalized name: caffeine 140 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 mg of ¹⁴C-labeled ibrutinib
Study: 25488966
Drug: Temsirolimus 25
Normalized name: temsirolimus 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus 25 mg IV once per week and Bevacizumab 10 mg/kg IV once every 2 weeks
Study: 25491305
Drug: Minocycline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (3 mg/kg/day for 8 weeks)
Study: 25491381
Drug: miniDOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: miniDOX regimen (D: 40 mg/m(2) iv, day 1; O: 80 mg/m(2) iv, day 1; C: 625 mg/m(2) po bid, day 1 to day 21, every 21 days; after six courses, only C was maintained)
Study: 25492104
Drug: GX/RT (gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GX/RT (gemcitabine and capecitabine/radiation therapy)
Study: 25492835
Drug: Nebivolol and
Normalized name: nebivolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol and Valsartan (5/160 mg/d initially, titrated to 20/320 mg/d)
Study: 25492923
Drug: nab-paclitaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-paclitaxel (100 mg/m(2) weekly for 3 weeks followed by a 1-week break)
Study: 25493435
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia and balanced anesthesia with short duration
Study: 25494662
Drug: Chronocort (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronocort (10 mg at 0700 h and 20 mg at 2300 h)
Study: 25495896
Drug: Ropinirole XL/PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole XL/PR (maximum 24 mg/d)
Study: 25495896
Drug: Ropinirole XL/PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole XL/PR (once-daily dosing)
Study: 25497558
Drug: Endostar (7.5mg/m(2)/d)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endostar (7.5mg/m(2)/d) for 7 days at weeks 1, 3, 5, and 7, with concurrent chemoradiotherapy (CCRT) including docetaxel (65mg/m(2)) and cisplatin (65mg/m(2)) on days 8 and 36, and thoracic radiation to a dose of 60-66Gy.
Study: 25497691
Drug: High-dose testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose testosterone treatment in female-to-male transsexuals
Study: 25497691
Drug: Antiandrogen and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiandrogen and estrogen treatment in male-to-female transsexuals
Study: 25498219
Drug: Sorafenib (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (800 mg) plus Everolimus (5 mg) once a day until disease progression or unacceptable toxic effects
Study: 25500329
Drug: Volatile organic
Normalized name: coal tar pitch volatiles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volatile organic compounds (VOCs) analysis in bile samples using selected ion flow tube mass spectrometry.
Study: 25500831
Drug: Intravenous tariquidar
Normalized name: Tariquidar
DrugBank: Tariquidar (DB06240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tariquidar infusion (2 mg/kg)
Study: 25500831
Drug: Intravenous tariquidar
Normalized name: Tariquidar
DrugBank: Tariquidar (DB06240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tariquidar infusion (4 mg/kg)
Study: 25500831
Drug: Injecting (11)C-dLop
Normalized name: (11)C-choline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injecting (11)C-dLop after intravenous tariquidar infusion (up to 6 mg/kg)
Study: 25500831
Drug: Oral tariquidar
Normalized name: Tariquidar
DrugBank: Tariquidar (DB06240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tariquidar
Study: 25501494
Drug: Intrathecal injection
Normalized name: BACLOFEN 50 ug in 1 mL INTRATHECAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal injection of bupivacaine 1.75 mg and fentanyl 15 μg
Study: 25501547
Drug: NKG2D receptor
Normalized name: NKG2D CAR-NK Cell
DrugBank: NKG2D-ACE2 CAR-NK Cell (DB15727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKG2D receptor expression on NK cells, CTLs, and NKT cells in alcoholic hepatitis
Study: 25501820
Drug: Helicobacter pylori
Normalized name: HELICOBACTER PYLORI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helicobacter pylori eradication treatment consisting of lansoprazole 30 mg, amoxicillin 1000 mg, and clarithromycin 500 mg orally twice daily for a week.
Study: 25502858
Drug: Simplified negative-pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simplified negative-pressure wound therapy